NVS News & Events

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.STRAIT OF HORMUZ:CBS News Senior White House Correspondent Weijia Jiangon X, "I called President Trump for some clarity on this post. He says the U.S. is not pulling assets in and around the Strait of Hormuz yet: 'At some point I will, not quite yet, but countries have to come in and take care of it. Iran has been decimated, but they're going to have to come in and do their own work.'"President Trump has expressed to his aides that he is prepared to complete the U.S. military campaign against Iran even if the Strait of Hormuz remains closed, The Wall Street Journal's Alexander Ward and Meridith McGraw. Trump and his advisors have concluded that efforts to open the chokepoint would extend the conflict beyond his timeline of four to six weeks, and the president has decided that the U.S. should achieve its main goals of crippling Iran's navy and its missile stocks while pressuring Tehran diplomatically to resume the free flow of trade, the report states.DELAYED DRUG LAUNCH:Drugmakers have delayed the launches of some medicines in Europe as the industry deals with U.S. pressure and pricing shifts from President Donald Trump, Maggie Fick, Bhanvi Satija and Dominique Patton of Reuters, citing executives, pricing policy shifts, and data shared with the journal. The White House has been pushing for lower prescription drug costs, with Trump looking to tie the cost for Americans to what is paid elsewhere. This has led drugmakers to pause bringing some medicines to European markets to avoid pulling down prices in the U.S. market. Publicly traded companies in the space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.

Drugmakers have delayed the launches of some medicines in Europe as the industry deals with U.S. pressure and pricing shifts from President Donald Trump, Maggie Fick, Bhanvi Satija and Dominique Patton of Reuters reports, citing executives, pricing policy shifts, and data shared with the journal. The White House has been pushing for lower prescription drug costs, with Trump looking to tie the cost for Americans to what is paid elsewhere. This has led drugmakers to pause bringing some medicines to European markets to avoid pulling down prices in the U.S. market. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

Latest data shows the largest indicative borrow rate increases among liquid option names include: Grabagun Digital Holdings Inc. (PEW) 5.85% +3.97, Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 33.13% +1.91, Mesoblast (MESO) 16.87% +1.06, T-REX 2X Long BMNR Daily Target ETF (BMNU) 24.42% +0.73, Olaplex Holdings (OLPX) 1.97% +0.64, iShares Turkey (TUR) 9.26% +0.53, Gold Bear 3x (DUST) 10.85% +0.42, Tenneco Inc (TEN) 1.75% +0.32, TSLR ETF (TSLR) 6.39% +0.30, and Novartis (NVS) 0.59% +0.26.

Novartis announced final two-year results from the Phase III APPLAUSE-IgAN study of Fabhalta in IgA nephropathy, IgAN. Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate slope, a key marker of kidney function, compared with placebo. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the New England Journal of Medicine and simultaneously presented as late-breaking data at the 2026 World Congress of Nephrology, WCN. "Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time," said Vlado Perkovic, MD, Professor of Medicine and Provost, University of New South Wales, and Steering Committee Co-Chair of the APPLAUSE-IgAN study. "These results are important because they show that Fabhalta can reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden."